events learn more about about us investors clinical data founder the team scientific advisors board of directors careers contact news & events learn more about about us investors clinical data founder the team scientific advisors board of directors careers contact diamond a one time intervention for type 2 diabetes healthcare professionals the diamond tantalus system is ce marked and available for commercial use . the diamond ii system is not ce marked currently . over 200 million people may benefit from our therapy type 2 diabetes already affects over 400 million people of which 60 % are obese . diamond is an alternative to injectable therapies insulin glp 1 agonists and others intended to treat obese type 2 diabetes patients who are resistant to oral medication . diamond will improve the lives of millions of people . current solutions patients under insulin or other injectable medication face a variety of challenges affecting their day to day life . often two or more daily blood sugar tests are needed and some patients may require four or more injections per day . common side effects and complications of insulin therapy include weight gain hypertension and in severe cases hypoglycemia shocks requiring hospitalization . additionally many patients can not tolerate glp 1 agonist therapy due to nausea vomiting and other gastrointestinal disturbances . these challenges ultimately lead to a lower compliance rate further complications and increased healthcare costs . treating diabetes with a single intervention diamond therapy is as effective as insulin but avoids the associated challenges and side effects . how does it work a small pacemaker like device is implanted under the abdominal skin and connected by electrodes to the stomach in a minimally invasive procedure . the device automatically detects when eating begins and sends gentle pulse signals gastric contractility modulation signals or gcm to the stomach muscles . as a result the diamond restores the physiological synchronization between food intake and natural hormone secretion and lowers post meal glucose levels . additionally gcm signals cause an earlier satiation effect resulting in sustained weight loss . the diamond therapy is completely reversible and does not affect the physiology of the body . improved glucose levels hba1c reduction of 1 % sustained long term results 300 patients treated in clinical studies 8 years clinical experience freedom from insulin diamond is a one time intervention does not cause hypoglycemia no daily needles no compliance issues natural pathways treatment minimal side effects fully reversible treatment sustained and significant weight lossand blood pressure reduction implantable device the diamond tantalus system is ce marked and available for commercial use . the diamond ii system is not ce marked currently . this small pulse generator is implanted under the abdominal skin and connected with leads to the stomach to deliver the diamond therapy . the device is only 30 cc in volume and allows wireless recharging . it can be used for up to 15 years before a replacement is needed . diamond has received ce mark and is approved for sale in europe australia and other international markets . diamond is not approved for use in the usa . physician tablet the tablet is used by certified physicians to set and control the therapy parameters of the implantable device through a wireless interface . image used for illustrative purposes only actual tablet model may vary . patient charger this external device is used to charge the implanted device wirelessly once a week by the patient at home . charging time is around 45 minutes . to fight the global diabetes pandemic we would ideally have an accessible cost effective easily compliant intervention prof. harold lebovitz new york ges diamond improves glycemic control and reduces body weight . hormone & metabolic research 20152 for the first time in many years i have hope . i now believe i can be there for my family and see my children have their own children . i can grow old with my wife . i can live the life that i want to live . mr. lo a type 2 diabetes patient under diamond therapy randomized trials indicate patients implanted with the diamond experience long term improvement in glycemic control as well as an improvement in other metabolic parameters . prof. bai rixing beijing we listened to physicians and diabetic patients and developed a new solution to make patients lives better . dr. mateusz zelewski ceo over 300 patients treated in clinical trials 83 % 1 improved their glycemic control 85 % 1 experienced weight reduction 3 years2 observation period in our long term study efficacy2 3 4 5 hba1c reduction of 1 % significant and sustained results over several years sustained weight loss of 5 10kg and significant reduction of blood pressure by 10 mmhg safety2 3 6 7 8 safe implantation procedure does not cause hypoglycemia minimal side effects our clinical data 1 lebovitz h.e. zalewski m. gastric electrical stimulation ges in t2dm improves long term glycemic control through a triglyceride dependent mechanism ; abstract op 0078 . presented at the idf world diabetes congress melbourne 2013 december 3 2013 melbourne . 2 lebovitz he ludvik b yaniv i et al. treatment of patients with obese type 2 diabetes with tantalus diamond gastric electrical stimulation normal triglycerides predict durable effects for at least 3 years . horm metab res . 2015 ; 47 6 456 62 . 3 wong sk kong ap luk ao et al. a pilot study to compare meal triggered gastric electrical stimulation and insulin treatment in chinese obese type 2 diabetes . diabetes technol ther . 2015 ; 17 4 283 90 . 4 lebovitz he ludvik b kozakowski j et al. gastric electrical stimulation treatment of type 2 diabetes effects of implantation versus meal mediated stimulation . a randomized blinded cross over trial . physiol rep. 2015 ; 3 7 . 5 lebovitz he ludvik b yaniv i et al. fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation . a novel lipotoxicity paradigm . diabet med . 2013 ; 30 6 687 93 . 6 bohdjalian a prager g rosak c et al. improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation . obes surg . 2009 ; 19 9 1221 7 . 7 sanmiguel cp conklin jl cunneen sa et al. gastric electrical stimulation with the tantalus system in obese type 2 diabetes patients effect on weight and glycemic control . j diabetes sci technol . 2009 ; 3 4 964 70 . 8 bohdjalian a prager g aviv r et al. one year experience with tantalus a new surgical approach to treat morbid obesity . obes surg . 2006 ; 16 5 627 34 . diamond has received ce mark and is approved for sale in europe australia and other international markets . diamond is not approved for use in the usa . 2016 metacure all rights reservedterms of use